Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings Roundup: Novartis, Eli Lilly (Part 4)

This article was originally published in PharmAsia News

Executive Summary

Novartis posted solid growth of 9% in Q1 in emerging markets, with China sales up 21%; Lilly reports strong sales in China lifted revenues by 11%.

You may also be interested in...



Lilly Right-Sizes Sales Force As It Pushes Its Pipeline Forward

The pharma is cutting costs as it continues to reel from revenues lost to generic competition. Meanwhile, it moves its late-stage pipeline forward in hopes of filling the gaps.

Symonds Steps Down As Novartis CFO, Replaced By Insider Kirsch

Novartis pharma division CFO Harry Kirsch is to replace Jon Symonds as group CFO. The company continues to benefit from the lack of a Diovan monotherapy generic in the U.S., reporting a 2% increase in sales and 7% increase in profits in the first quarter.

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Topics

Related Companies

UsernamePublicRestriction

Register

SC084449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel